ArticleNature protocols2015
Using the GEMM-ESC strategy to study gene function in mouse models.
Article in Nature protocols, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Constitutive YAP activation in distal nephron segments disrupts epithelial identity and nephron patterning.JCI insight · 2026Article
- Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models.Cancer research communications · 2025Article
- Transcription Factor 21 Regulates Cardiac Myofibroblast Formation and Fibrosis.Circulation research · 2025Article
- Generation of albino C57BL/6J mice by CRISPR embryo editing of the mouse tyrosinase locus.Journal of genetics · 2025Article
- Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.Cancer letters · 2024Review
- Advances in Making Cancer Mouse Models More Accessible and Informative through Non-Germline Genetic Engineering.Cold Spring Harbor perspectives in medicine · 2024Review
- Development of a mouse embryonic stem cell model for investigating the functions of the linker histone H1-4.FEBS open bio · 2024Article
- MCUb is an inducible regulator of calcium-dependent mitochondrial metabolism and substrate utilization in muscle.Cell reports · 2023Article
- INFRAFRONTIER: mouse model resources for modelling human diseases.Mammalian genome : official journal of the International Mammalian Genome Society · 2023Review
- The CRISPR/Cas System in Human Cancer.Advances in experimental medicine and biology · 2023Article
- Article
- CRISPR in cancer biology and therapy.Nature reviews. Cancer · 2022Review
- Novel Mouse Models for Cancer Immunology.Annual review of cancer biology · 2022Article
- Review
- Review
- Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.Frontiers in immunology · 2021Review
- Strategies to Study the Functions of Pseudogenes in Mouse Models of Cancer.Methods in molecular biology (Clifton, N.J.) · 2021Review
- AnCancer discovery · 2020Article
- TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.Genes & development · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Preclinical in vivo validation of target genes for therapeutic intervention requires careful selection and characterization of the most suitable animal model in order to assess the role of these genes in a particular process or disease. To this end, genetically engineered mouse models (GEMMs) are typically used. However, the appropriate engineering of these models is often cumbersome and time consuming. Recently, we and others described a modular approach for fast-track modification of existing GEMMs by re-derivation of embryonic stem cells (ESCs) that can be modified by recombinase-mediated transgene insertion and subsequently used for the production of chimeric mice. This 'GEMM-ESC strategy' allows for rapid in vivo analysis of gene function in the chimeras and their offspring. Moreover, this strategy is compatible with CRISPR/Cas9-mediated genome editing. This protocol describes when and how to use the GEMM-ESC strategy effectively, and it provides a detailed procedure for re-deriving and manipulating GEMM-ESCs under feeder- and serum-free conditions. This strategy produces transgenic mice with the desired complex genotype faster than traditional methods: generation of validated GEMM-ESC clones for controlled transgene integration takes 9-12 months, and recombinase-mediated transgene integration and chimeric cohort production takes 2-3 months. The protocol requires skills in embryology, stem cell biology and molecular biology, and it is ideally performed within, or in close collaboration with, a transgenic facility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.